Journey Colab is a pioneering pharmaceutical startup focused on developing psychedelic therapies for addiction treatment. Their integrated care model combines psychedelic therapeutics with psychotherapy and community support, aiming to provide durable remission for patients suffering from addiction. The company is advancing its own drug program, JOUR-5700, Mescaline HCl for Alcohol Use Disorder, and collaborates with addiction treatment centers across the U.S. Journey Colab is backed by world-class investors and emphasizes equitable access to care, particularly for Indigenous communities. With a significant market opportunity, given that over 20 million Americans suffer from addiction, the company is positioned to disrupt traditional addiction treatment paradigms.
Something looks off?